Searchable abstracts of presentations at key conferences in endocrinology

ea0081p678 | Pituitary and Neuroendocrinology | ECE2022

Treatment of cushing’s disease (CD) after primary failure of pituitary surgery or recurrence: evaluation of long-term control by medical treatment

Ghalawinji Adel , Cristante Justine , Lefournier Virginie , Chaffanjon Philippe , muller Marie , Gay Emmanuel , Olivier Chabre

Introduction: Pituitary surgery is the first line treatment for most patients with Cushing’s disease (CD) but after failure or recurrence after surgery 3 main strategies can be proposed: medical treatment (MT), a 2 nd pituitary surgery, bilateral adrenalectomy (BA). Pituitary radiotherapy is a 4th strategy, generally combined with one of the 3 others. Medical treatment (MT) emerges as an attractive strategy but there are little data on long-term control after f...

ea0063gp191 | Adrenal and Neuroendocrine - Clinical | ECE2019

Pneumocystis pneumonia as a major complication of medical treatment for severe Cushing’s syndrome linked either to ectopic ACTH secretion or to Cushing’s disease

Cristante Justine , Mallaret Michel , Tourvieilhe Laura , Carreau Agnes , Vaillant Tiphaine , Yoldjian Isabelle , Chabre Olivier

Several cases of pneumocystosis developing after lowering cortisol serum level have been reported, mostly in patients with ectopic Cushing’s syndrome. We report here 2 cases of pneumocystosis which developed after initiation of treatment with metyrapone, one in a patient with Cushing’s disease, and the second in a patient with ectopic ACTH secretion by a prostate endocrine carcinoma. Both cases presented severe Cushing’s syndrome. We then analyzed the periodic s...

ea0056p837 | Pituitary - Clinical | ECE2018

Cushing’s disease with negative or inconclusive MRI: reassessment of transphenoidal surgery at the age of medical treatment. Post operative remission rate in 184 patients including 86 with negative or inconclusive MRI

Cristante Justine , Lefournier Virginie , Sturm Nathalie , Guy Passagia Jean , Gay Emmanuel , Chabre Olivier

When pituitary MRI show a typical imaging of adenoma, it is agreed that transsphenoidal surgery is the reference treatment with remission achieved in about 80% of patients. If MRI is negative or inconclusive, some authors consider that the results of surgery are less successful, and propose medical treatment as a first line therapy, despite a disease control rate between 30 and 70%. Since 1990, our center chose to systematically explore patients with ACTH dependent hypercortic...

ea0090rc6.1 | Rapid Communications 6: Endocrine-related Cancer | ECE2023

Aberrant activation of Wnt/β-Catenin signaling pathway drives the expression of poor prognosis-associated microRNAs in adrenocortical cancer

Cristante Justine , El Sayed Soha Reda , Denis Josiane , Ragazzon Bruno , Constanze Hantel , Chabre Olivier , Guyon Laurent , Cherradi Nadia

Adrenocortical carcinoma (ACC) is a rare malignancy with dismal prognosis. Deregulated microRNA (miRNA) expression has been implicated in ACC aggressiveness. Nevertheless, the mechanisms underlying such deregulations remain unknown. Aberrant Wnt/β-Catenin signaling has been reported in about 40% of ACC and is associated with poor outcome. In the present work, we aimed to investigate the link between constitutive activation of Wnt/β-Catenin pathway and miRNA expressio...

ea0099p2 | Adrenal and Cardiovascular Endocrinology | ECE2024

Prospective, multi-country, observational study of patients with endogenous Cushing’s syndrome exposed to Ketoconazole (using the existing European Registry on Cushing’s Syndrome (ERCUSYN)), to assess drug use, safety and effectiveness

Webb Susan , Santos Alicia , Aulinas Maso Anna , Tomsic Karin Zibar , Amaral Claudia , Feelders Richard , Ragnarsson Oskar , Ferrante Emanuele , Ceccato Filippo , Chabre Olivier , Cristante Justine , Hanzu Felicia , Reincke Martin , Chanson Philippe , Tabarin Antoine , Sequeira Duarte Joao , Guelho Daniela , Fajardo Carmen , Bostnavaron Martine , Bou Nader Myriam , Bertherat Jerome , Brue Thierry

Background: Ketoconazole is a steroidogenesis inhibitor approved in Europe for the treatment of endogenous Cushing’s syndrome (CS) based on retrospective studies published over 3 decades. We present interim data from the first prospective observational, multicenter, international study on ketoconazole, a non-interventional PASS (Post-Authorization Safety study) requested by EMA at the time of registration to confirm ketoconazole good tolerance and effectiveness. This stud...